A critical issue in the management of relapsing MS (RMS) is the discontinuation of disease-modifying treatments (DMT) due to lack of efficacy, intolerability or impending risks. With new therapeutic agents introduced into the treatment of RMS, immediate- and long-term consequences of sequential drug use, as well as the effect of the sequence in which the drugs are given, are unclear but may affect efficacy, adverse events, and long-term immunocompetence. In the absence of clinical studies specifically addressing these concerns, observations from clinical practice are of particular value in guiding current management algorithms. Prompted by a study published by Ferraro et al. in this journal, we set out to provide an overview of the published real-world evidence on the effectiveness and safety of switching from fingolimod to another DMT in patients with active RMS. Seventeen publications reporting relevant information were identified. The literature suggests that immune cell depletion induced by alemtuzumab or ocrelizumab is associated with an increased risk of relapse and worsening disability in patients switching from fingolimod compared to patients switching from other therapeutic agents. However, the evidence reported for natalizumab and cladribine is inconclusive. While shortening of the washout period may limit early disease reactivation after fingolimod discontinuation, there is no strong evidence that the duration of the washout period or the absolute lymphocyte count at baseline are predictors of attenuated long-term efficacy. Further real-world studies are required to better understand outcomes among patients who are under-represented in controlled trials.

Brain and Mind Centre University of Sydney Sydney Australia

Department of Neurology Medical Faculty Heinrich Heine University Düsseldorf Moorenstraße 5 40225 Düsseldorf Germany

Department of Neurology Medical University of Vienna Vienna Austria

Department of Neurology Palacky University Olomouc Olomouc Czech Republic

LWL Clinics Muenster Muenster Germany

Zobrazit více v PubMed

McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325(8):765–779. PubMed

Lorscheider J, et al. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis. Mult Scler. 2018;24(6):777–785. PubMed

Baroncini D, et al. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. Mult Scler. 2016;22(10):1315–1326. PubMed

Sormani MP, Laroni A. Approved drugs for multiple sclerosis: the challenge of choice. Lancet Neurol. 2017;16(4):252–253. PubMed

Hartung HP, Meuth SG, Thompson AJ. Paradigm shifts: early initiation of high-efficacy disease-modifying treatment in multiple sclerosis. Mult Scler. 2021;27(10):1473–1476. PubMed

Hatcher SE, et al. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol. 2016;73(7):790–794. PubMed

Ruck T, et al. Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci. 2015;16(7):16414–16439. PubMed PMC

Lunemann JD, et al. Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol. 2020;16(1):56–62. PubMed

Polman CH, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302. PubMed PMC

Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173. PubMed

Kappos L, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401. PubMed

Chitnis T, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018;379(11):1017–1027. PubMed

Cohen JA, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–415. PubMed

Barbin L, et al. Comparative efficacy of fingolimod vs natalizumab: a French multicenter observational study. Neurology. 2016;86(8):771–778. PubMed PMC

Pfeuffer S, et al. Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation. J Neurol. 2019;266(1):165–173. PubMed

Vollmer B, et al. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019;407:116498. PubMed

Wicks P, et al. The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis. BMC Res Notes. 2016;9(1):434. PubMed PMC

Polman CH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910. PubMed

Rudick RA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911–923. PubMed

Giovannoni G, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416–426. PubMed

Giovannoni G, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24(12):1594–1604. PubMed

Pfeuffer S et al (2021) Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres. Mult Scler 13524585211012227 PubMed PMC

Havrdova E, et al. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Mult Scler J Exp Transl Clin. 2018;4(1):2055217318760642. PubMed PMC

Cellerino M, et al. Severe disease activity in MS patients treated with cladribine after fingolimod withdrawal. J Neurol Sci. 2020;418:117156. PubMed

Radlberger RF, et al. Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine. Mult Scler Relat Disord. 2021;48:102727. PubMed

Coles AJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology. 2017;89(11):1117–1126. PubMed PMC

Havrdova E, et al. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology. 2017;89(11):1107–1116. PubMed PMC

Willis M, et al. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2017;4(2):e320. PubMed PMC

Bernard-Valnet R, et al. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab. Mult Scler Relat Disord. 2018;25:216–218. PubMed

Wehrum T, et al. Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis. Neurology. 2018;90(7):e601–e605. PubMed

Eichau S (2017) Efficacy of Alemtuzumab in patients who switched from Fingolimod. ECTRIMS Online Library. 200817; P1162

Huhn K, et al. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study. J Neurol. 2018;265(7):1521–1527. PubMed

Frau J, et al. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study. J Neurol. 2019;266(10):2440–2446. PubMed

Alcala C, et al. Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. J Neurol. 2019;266(3):726–734. PubMed

Pato A, SSDM, Costa E, López Real A, Álvarez Rodriguez E, González Quintanilla V, González Suárez I, Álvarez L, Lorenzo JR, Arias Gómez M, Lema Devesa C, Amigo Jorrín MC, Peña Martínez J (2018) Efficacy and safety of alemtuzumab after switching from a second line therapy. ECTRIMS Online Library. Pato A. 10/12/18; 229053; P1213

Theodorsdottir A, MM, Schreiber KI, Kant M, Rasmussen PV, Hansen V, Bech D, Schmidt MF, Frederiksen JL, Sellebjerg F, Illes Z (2019) Alemtuzumab treatment in Denmark: a national study based on the Danish MS Registry. ECTRIMS Online Library. Theodorsdottir A. 09/13/19; 278551; P1349 PubMed

Pfeuffer S, et al. Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab. J Neurol Neurosurg Psychiatry. 2021;92:1007–1013. PubMed PMC

Signoriello E, et al. Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy. Mult Scler. 2021 doi: 10.1177/13524585211005657. PubMed DOI

Boudot de la Motte M, et al. Challenges of switching towards anti-CD20 monoclonal antibodies in RR-MS: a monocentric study. Mult Scler Relat Disord. 2021;52:102981. PubMed

Schmidt S, Schulten T. Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases. Ther Adv Neurol Disord. 2019;12:1756286419846818. PubMed PMC

Hauser SL, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221–234. PubMed

Hauser SL, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546–557. PubMed

Hu Y, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128(2):260–270. PubMed PMC

Kahari L, et al. Transcytosis route mediates rapid delivery of intact antibodies to draining lymph nodes. J Clin Invest. 2019;129(8):3086–3102. PubMed PMC

Theil D, et al. Imaging mass cytometry and single-cell genomics reveal differential depletion and repletion of B-cell populations following ofatumumab treatment in cynomolgus monkeys. Front Immunol. 2019;10:1340. PubMed PMC

Gross RH, Corboy JR. Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies. Continuum (Minneap Minn) 2019;25(3):715–735. PubMed

Francis G, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler. 2014;20(4):471–480. PubMed

Berger B, et al. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation. J Neuroimmunol. 2015;282:118–122. PubMed

Ferraro D, et al. Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. J Neurol. 2021 doi: 10.1007/s00415-021-10708-1. PubMed DOI

Rolfes L, et al. Skin reactions in patients with multiple sclerosis receiving cladribine treatment. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):e990. PubMed PMC

Mateo-Casas M, et al. Severe skin reactions associated with cladribine in people with multiple sclerosis. Mult Scler Relat Disord. 2020;43:102140. PubMed

Kalincik T, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol. 2017;16(4):271–281. PubMed

Comi G, et al. Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. Neurol Sci. 2020;41(10):2843–2851. PubMed PMC

Novartis G. prescribing information. East Hanover: Novartis Pharmaceuticals Corporation; 2016.

Lebrun C, et al. Only follow-up of memory B cells helps monitor rituximab administration to patients with neuromyelitis optica spectrum disorders. Neurol Ther. 2018;7(2):373–383. PubMed PMC

Baker D, et al. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm. 2017;4(4):e360. PubMed PMC

Grutzke B, et al. Fingolimod treatment promotes regulatory phenotype and function of B cells. Ann Clin Transl Neurol. 2015;2(2):119–130. PubMed PMC

Kemmerer CL, et al. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-beta, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab. PLoS ONE. 2020;15(7):e0235449. PubMed PMC

Blumenfeld S, Staun-Ram E, Miller A. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFbeta in patients with Multiple Sclerosis. J Autoimmun. 2016;70:40–51. PubMed

Traub JW, et al. Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients. J Neuroinflammation. 2019;16(1):228. PubMed PMC

Friess J, et al. Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis. Sci Rep. 2017;7:42087. PubMed PMC

Dominguez-Villar M, et al. Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo. J Autoimmun. 2019;96:40–49. PubMed PMC

Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab